Title:
USE OF CAJANOLACTONE A IN PREPARING FORMULATION FOR TREATING ACQUIRED OBESITY AND CONCOMITANT DISEASES THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/011914
Kind Code:
A1
Abstract:
Disclosed is a use of cajanolactone A in preparing a formulation for treating acquired obesity and concomitant diseases thereof. The inventor discovered unexpectedly in research that the oral intake of cajanolactone A effectively inhibits increases caused by non-congenital factors (high-fat diet or ovarian removal) in weight gain, total body fat percentage, subcutaneous fat percentage and visceral fat percentage of obese animals in obese mouse models, thereby protecting impaired liver function. The oral intake of cajanolactone A also effectively reduces weight gain, average cell diameter, and average cell area of retroperitoneal and inguinal white adipose tissues, significantly improving liver tissue fat deposition and liver function. Cajanolactone A has very broad clinical application prospects when used as a formulation for treating or improving obesity and obesity-related fatty liver disease caused by a high-fat high-calorie diet, or when used as a formulation for treating or improving obesity of postmenopausal women.
More Like This:
Inventors:
SHEN XIAO-LING (CN)
LUO ZHUO-HUI (CN)
HU YING-JIE (CN)
FU LIN-CHUN (CN)
LUO ZHUO-HUI (CN)
HU YING-JIE (CN)
FU LIN-CHUN (CN)
Application Number:
PCT/CN2020/130275
Publication Date:
January 20, 2022
Filing Date:
November 20, 2020
Export Citation:
Assignee:
GUANGZHOU UNIV OF CHINESE MEDICINE GUANGZHOU INSTITUTE OF CHINESE MEDICINE (CN)
GUANGZHOU YUNZHONG BIOLOGICAL TECH CO LTD (CN)
GUANGZHOU YUNZHONG BIOLOGICAL TECH CO LTD (CN)
International Classes:
A61P1/16; A61K31/366; A61P3/04
Domestic Patent References:
| WO2013013417A1 | 2013-01-31 |
Foreign References:
| CN103356607A | 2013-10-23 |
Other References:
LUO ZHUO-HUI; LIU ZHI-WEN; MAO YU; SHU RONG; FU LIN-CHUN; YANG RUI-YI; HU YING-JIE; SHEN XIAO-LING: "Cajanolactone A, a stilbenoid from cajanus cajan, prevents ovariectomy-induced obesity and liver steatosis in mice fed a regular diet", PHYTOMEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 78, 24 July 2020 (2020-07-24), AMSTERDAM, NL , XP086270004, ISSN: 0944-7113, DOI: 10.1016/j.phymed.2020.153290
LUO QINGFENG: "Hypocholesterolemic Effect of Stilbene Extract from Cajanus Cajan L.on Serum and Hepatic Lipid in Diet-Induced Hyperlipidemic Mice", ACTA PHARMACEUTICA SINICA, YAOXUE XUEBAO, CN, 31 December 2008 (2008-12-31), CN , XP055889245, ISSN: 0513-4870
LUO QINGFENG: "Hypocholesterolemic Effect of Stilbene Extract from Cajanus Cajan L.on Serum and Hepatic Lipid in Diet-Induced Hyperlipidemic Mice", ACTA PHARMACEUTICA SINICA, YAOXUE XUEBAO, CN, 31 December 2008 (2008-12-31), CN , XP055889245, ISSN: 0513-4870
Attorney, Agent or Firm:
GUANGZHOU HUAXUE INTELLECTUAL PROPERTY AGENCY CO., LTD. (CN)
Download PDF: